dactolisib has been researched along with Influenza--Human* in 2 studies
1 trial(s) available for dactolisib and Influenza--Human
Article | Year |
---|---|
TORC1 inhibition enhances immune function and reduces infections in the elderly.
Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant ( Topics: Aged; Antibodies, Viral; Communicable Diseases; Dose-Response Relationship, Drug; Everolimus; Humans; Imidazoles; Immunity; Influenza, Human; Mechanistic Target of Rapamycin Complex 1; Quinolines; Up-Regulation; Vaccination | 2018 |
1 other study(ies) available for dactolisib and Influenza--Human
Article | Year |
---|---|
Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention.
Influenza is a worldwide health and financial burden posing a significant risk to the immune-compromised, obese, diabetic, elderly, and pediatric populations. We identified increases in glucose metabolism in the lungs of pediatric patients infected with respiratory pathogens. Using quantitative mass spectrometry, we found metabolic changes occurring after influenza infection in primary human respiratory cells and validated infection-associated increases in c-Myc, glycolysis, and glutaminolysis. We confirmed these findings with a metabolic drug screen that identified the PI3K/mTOR inhibitor BEZ235 as a regulator of infectious virus production. BEZ235 treatment ablated the transient induction of c-Myc, restored PI3K/mTOR pathway homeostasis measured by 4E-BP1 and p85 phosphorylation, and reversed infection-induced changes in metabolism. Importantly, BEZ235 reduced infectious progeny but had no effect on the early stages of viral replication. BEZ235 significantly increased survival in mice, while reducing viral titer. We show metabolic reprogramming of host cells by influenza virus exposes targetsĀ for therapeutic intervention. Topics: Animals; Cell Survival; Drug Evaluation, Preclinical; Female; Glucose; Glutamine; Humans; Imidazoles; Influenza, Human; Lung; Metabolic Flux Analysis; Mice, Inbred C57BL; Orthomyxoviridae Infections; Proteome; Quinolines; Toll-Like Receptors | 2017 |